Accessibility StatementSkip Navigation Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers) Patent further broadens and strengthens GLIX1 patent protection until 2040, with a possible patent-term extension of up to five years TEL AVIV, Israel, Nov. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and ...

Accessibility StatementSkip Navigation The 155,000-square-foot facility is part of Modine's multi-year $100 million investment announced in July to scale production of Airedale by Modineâ"¢ data center cooling solutions. The facility will create more than 300 new jobs by March 2026, with approximately 430 employees expected at the site within three years. "Franklin's collaborative spirit, a strong workforce and support for industrial growth made it an ideal location for this expansion," said John Williams, ...

SHANGHAI, Nov. 17, 2025 /PRNewswire/ -- H World Group Limited (NASDAQ: HTHT; HKEX: 01179), one of the world's leading hospitality groups, delivered strong third-quarter results for 2025, with continued momentum across its asset-light expansion, loyalty ecosystem, and digital capabilities. Asset-light Strategy Continues to Drive High-quality Growth Continue Reading A Hanting Hotel room, H World's flagship economy brand Hotel GMV reached RMB 30.6 billion, up 17.5% year-on-year, while total revenue grew 8.1% y ...

Accessibility StatementSkip Navigation Stockholders to Receive $42.15 per Share in Cash Representing a 41% Premium to the Unaffected Share Price CHARLOTTE, N.C., Nov. 17, 2025 /PRNewswire/ --Â Sealed Air Corporation ("Sealed Air" or the "Company") (NYSE: SEE), a leading global provider of food and protective packaging solutions, announced today that it has entered into a definitive agreement to be acquired by funds affiliated with CD&R, a leading private investment firm with deep experience in the industria ...

Core Insights - BD (Becton, Dickinson and Company) has received WHO prequalification for its Onclarity™ HPV Assay, enhancing access to cervical cancer screening in low- and middle-income countries [1][4]. Product Details - The BD Onclarity™ HPV Assay detects 14 high-risk HPV types, allowing for individual identification of six high-risk types and three genotype groups, which aids in risk stratification and patient management [2][3]. - The assay is approved for self-collection, including at-home self-collection in countries recognizing the CE mark, thus improving access in resource-limited settings [2][4]. Impact on Healthcare - The ability to identify more individual HPV types enables clinicians to manage high-risk cases more effectively and guide follow-up for low-risk patients, ensuring appropriate care and reducing resource demand [3][4]. - WHO emphasizes the importance of regular screening to prevent cervical cancer, which is the fourth most common cancer in women globally, with a woman dying from it every 90 seconds [7]. System Features - The BD Viper™ LT System is designed for decentralized testing, featuring a compact design that automates sample preparation and amplification, making it suitable for labs with limited infrastructure [5]. - The BD COR™ System offers high-throughput automation for centralized labs, capable of processing nearly 1,650 tests and delivering up to 1,000 results in 24 hours, maximizing efficiency [6].

Core Insights - Target Hospitality Corp. announced a 400-bed community expansion, increasing the size of its previously announced 250-bed data center community by 160%, resulting in a capacity for up to 650 individuals, with potential growth to 1,500 individuals [1][3] Financial Impact - The Community Expansion is expected to generate approximately $40 million in committed minimum revenue over its initial two-year term, with the total contract value for the Expanded Data Center Community rising to about $83 million, reflecting a more than 90% increase from the initial contract value of $43 million [2][3] Capital Investment - Target Hospitality plans to invest approximately $10 to $15 million from its existing asset portfolio to complete the Community Expansion, with construction set to begin in Q4 2025 and expected completion in Q1 2026 [3] Market Demand - The expansion reflects a growing demand for customized hospitality solutions, particularly in support of AI and data center infrastructure, positioning Target as a critical player in the data center value chain [4][5] Strategic Positioning - The rapid increase in community size and the company's ability to respond to customer demand highlight the advantages of Target's vertically integrated accommodations platform, establishing it as a leading provider of tailored hospitality solutions [5]

Core Insights - Target Hospitality Corp. announced a 400-bed community expansion, increasing the size of its previously announced 250-bed data center community by 160%, resulting in a capacity for up to 650 individuals, with potential growth to 1,500 individuals [1][3] Financial Impact - The Community Expansion is expected to generate approximately $40 million in committed minimum revenue over its initial two-year term through March 2028, with the total contract value for the Expanded Data Center Community rising to about $83 million, reflecting a more than 90% increase from the initial contract value of $43 million [2][3] Capital Investment - Target Hospitality plans to utilize a portion of its existing asset portfolio for the Community Expansion, with a capital investment estimated between $10 million and $15 million, and construction is set to begin in Q4 2025, with completion anticipated in Q1 2026 [3] Market Demand - The expansion reflects the growing demand for customized hospitality solutions, particularly in support of AI and data center infrastructure, positioning Target as a critical player in the data center value chain [4][5] Strategic Positioning - The rapid increase in community size and the company's ability to respond to customer demand highlight the advantages of Target's vertically integrated accommodations platform, establishing it as a leading provider of tailored hospitality solutions in a rapidly expanding market [5][6]

Accessibility StatementSkip Navigation Transaction concludes a multi-phase program through which Hut 8 stabilized and strengthened the Portfolio following its acquisition out of bankruptcy MIAMI, Nov. 17, 2025 /PRNewswire/ --Â Hut 8 Corp. (Nasdaq, TSX: HUT) ("Hut 8" or the "Company"), an energy infrastructure platform integrating power, digital infrastructure, and compute at scale to fuel next- generation, energy-intensive use cases, today announced that it has entered into a definitive share purchase agree ...

Core Points - TNMP, a subsidiary of TXNM Energy, filed for a base rate review reflecting significant growth since the last filing seven years ago [1][2] - The filing requests recovery of $2.8 billion in rate base, a return on equity of 10.4%, and an equity ratio of 47.54% [2][3] - Current rates are based on a rate base of $835 million, with an allowed return on equity of 9.65% and a 45% equity ratio [2][3] Rate Filing Components - The request includes increased operations and maintenance costs, changes in deferred federal income tax amortizations, and updates to depreciation rates [3][4] - TNMP is also requesting $20.5 million for Hurricane Beryl restoration costs, to be recovered over five years [4] - If approved, new rates are expected to take effect in mid-2026 [4] Financial Summary - Key components of the rate filing include a total revenue requirement increase of $141.8 million, with a net rate increase of $33.8 million [5] - Major operational drivers include vegetation management, headcount increases, catastrophe reserve increases, and insurance premiums [9] - The core rate base growth includes returns on investments and distribution investments from January to June 2025 [7]

Accessibility StatementSkip Navigation CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 P ...